Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
RNAtrium Therapeutics, Inc. logo

Atrium Therapeutics, Inc. (RNA)

NASDAQ Global Select · Currency in USD
$8.20 ▲ +0.04 (+0.49%)
At close: Oct 23, 4:00 PM ET. Market closed.
$8.15 ▼ -0.05 (-0.61%)
After hours: Oct 23, 7:23 PM ET

Summary

Previous Close
$8.16
Open
$8.06
Day's Range
$7.79 – $8.21
52 Week Range
$7.49 – $16.77
Volume
192,644
Avg. Volume
254,219
Market Cap
$140.27M
Beta (5Y Monthly)
0.37
PE Ratio (TTM)
--
EPS (TTM)
-$5.45
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$22.50

Profile: Atrium Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
511
CEO
Kathleen Gallagher

Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases.

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate -$0.81 · Revenue est. $15.00M
DateEst.Actual
Aug 13, 2026-$1.42-$1.18Beat
May 14, 2026-$1.05-$0.97Beat
Feb 26, 2026-$1.24-$0.61Beat
May 8, 2025-$0.90-$0.90Beat
Feb 27, 2025-$0.79-$0.80Miss
Nov 7, 2024-$0.71-$0.65Beat

Analyst view

Consensus price target
$22.50 ▲ +174.4%
Range $15.00 – $25.00
Rating: Buy
Buy 50% · Hold 50% · Sell 0%

Get free alerts on RNA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.